mrcc: when is tki/i-o combination therapy appropriate?
Published 5 years ago • 973 plays • Length 9:05Download video MP4
Download video MP3
Similar videos
-
3:15
tki/i-o therapy in mrcc
-
4:53
emerging tki/i-o options in mrcc
-
7:55
mrcc: identifying and managing aes in tkis and io therapy
-
4:18
mrcc: how an approved i-o regimen impacts treatment
-
8:07
vegf tki immunotherapy combinations for mrcc
-
2:17
tki therapy versus i-o therapy in mrcc
-
7:43
mrcc: resistance to vegf and i/o
-
4:27
vegf-tki therapy in first-line mrcc
-
1:19
dr. beckermann on tki/immunotherapy combinations in mrcc
-
5:11
selecting immunotherapy versus vegf tki for mrcc
-
6:56
role of tkis in intermediate or poor-risk mrcc
-
5:15
favorable-risk rcc: frontline vegf tki/io combinations
-
5:01
vegf tki therapy after i/o in mrcc
-
6:30
second-line therapy after i/o in mrcc
-
3:15
a novel approach: tki/i-o combinations in rcc
-
6:22
mtor/tki combination therapy in kidney cancer
-
5:12
rationale for combination therapy in mrcc
-
3:43
the rationale behind combination therapy in mrcc
-
3:42
second-line combination therapy in mrcc